



Pharmaids Pharmaceuticals Limited

Date: 07.08.2025

To
The Corporate Relations Department
BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street
Mumbai – 400001

Dear Sir/Madam,

Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018

Sub: Change in Management – Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company in their Meeting held today i.e., Thursday, August 07, 2025, have, inter alia considered and:

1. Based on the recommendations of the Nomination and Remuneration Committee, approved the appointment of following individuals who are designated as Senior Management Personnel of the Company, with effect from August 07, 2025.
 - a. Dr. Sidde Gowda as Vice President – Operations
 - b. Dr. Jagadeesh M as Vice President – Discovery Services
 - c. Mr. Shivananda Murthy as Chief Information Officer
2. Resignation of Dr. S Prasad as the Chief Executive Officer of the Company with effect from the close of business hours on August 07, 2025, due to his personal reasons. Consequently, he shall also cease to be a Key Managerial Personnel of the Company.

The disclosure as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024 including amendments thereon, with respect to the aforesaid appointments & resignation is enclosed as **Annexure A**.

The Board Meeting commenced at 03:30 P.M. and concluded at 04:20 P.M.

Kindly take the same on your record and oblige.

For Pharmaids Pharmaceuticals Limited

Prasanna Subramanya Bhat
(Company Secretary & Compliance Officer)

Details with respect to appointment of Senior Management Personnel of the Company, as required under Regulation 30 of SEBI (LODR) Regulations, 2015 and SEBI Master Circular dated November 11, 2024.

S.No.	Particulars	Details		
1	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment of Dr. Sidde Gowda as Vice President – Operations	Appointment of Dr. Jagadeesh M as Vice President – Discovery Services	Appointment of Mr. Shivananda Murthy as Chief Information Officer
2	Date of appointment and Term of appointment	August 07, 2025	August 07, 2025	August 07, 2025
3	Brief Profile	Provided below	Provided below	Provided below
4	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable	Not Applicable	Not Applicable

Brief profile of Dr. Sidde Gowda

Dr. Sidde Gowda is seasoned pharmaceutical industry professional with more than 3 decades of extensive experience in various functional areas within leading global and Indian pharmaceutical companies. His area of expertise includes, Research, CRDMO, Drug Manufacturing Operations, Quality and Regulatory Affairs. He has worked with many global pharma giants like, GSK, Apotex and Sami Sabinsa and has proven track record of successful leadership.

Brief profile of Dr. Jagadeesh M

Dr. Jagadeesh is a seasoned scientific leader with over 20 years of experience in the drug discovery CRO industry, bringing strategic leadership and a strong track record of innovation. He has collaborated extensively with global pharmaceutical companies, leading the successful execution of 20+ drug discovery programs from hit identification to lead optimization. A recognized thought leader in the field, he has authored 11 peer-reviewed publications and holds inventorship on more than 10 international patents, reflecting his commitment to advancing science and delivering impactful solutions.



Brief profile of Mr. Shivananda Murthy

Mr. Shivananda Murthy M V holds a Master of Science (M.Sc.) in Information Technology, a Master of Arts (M.A.) in Sociology, and a Diploma in Computer Programming (DCP), bringing over 35 years of experience in the IT and Contract Research Organization (CRO) industry. With a strong focus on regulatory compliance and operational excellence in preclinical research environments, he spent 30 years at Eurofins Advinus, Bangalore, and 5 years at Bioneds India Private Limited, leading numerous high-impact technology initiatives in alignment with GLP, FDA, and EMA guidelines.

Details with respect to resignation of CEO of the Company, as required under Regulation 30 of SEBI (LODR) Regulations, 2015 and SEBI Master Circular dated November 11, 2024.

Sl. No.	Particulars	Details
1	Reason for change viz. appointment, resignation, removal, death or otherwise	Dr. S Prasad has tendered his resignation as Chief Executive Officer of the Company due to his personal reasons as per the enclosed resignation letter.
2	Date of appointment/ cessation	Resigned with effect from the close of business hours on August 07, 2025.
3	Brief Profile	Not Applicable
4	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

For Pharmaids Pharmaceuticals Limited

Prasanna Subramanya Bhat
(Company Secretary & Compliance Officer)

Date: August 7, 2025

To

The Board of Directors

Pharmaids Pharmaceuticals Limited

Unit #201, Brigade Rubix, 20/14, HMT Factory Road

Peenya Plantation, Bangalore - 560013, India

Subject: Resignation from the Position of Chief Executive Officer

Dear Sir/Madam,

I, Dr. S. Prasad, hereby tender my resignation from the position of Chief Executive Officer of Pharmaids Pharmaceuticals Limited, with effect from close of business hours on August 07, 2025.

This has been a carefully considered decision, made after much personal reflection. I believe this is the right time for me to step aside and focus on personal priorities outside the organization.

I would like to express my sincere gratitude to the Board of Directors and the entire team at Pharmaids for their continued trust and support throughout my tenure. It has been a privilege to lead the organization, and I take great pride in the progress we have made together.

I wish Pharmaids Pharmaceuticals continued success and growth in the years to come.

Thank you.

Yours sincerely,



07/08/2025

Dr. S. Prasad